Abstract

Introduction: We present an unusual case of a 28-year-old rheumatologic male patient who developed eosinophilia while he was on etanercept therapy previously and then on golimumab.

Case Representation: Although eosinophilia is rarely reported in the literature as a side-effect of various Tumor Necrosis Factor-alpha (TNF-alpha) antagonists, it represents a riddle about the future treatments of these patients since the persistence of therapy might lead to the onset of dermatologic or visceral eosinophilic complications in such patients.

Conclusion: Furthermore, the pathogenesis of eosinophilia is still unknown, and all the proposed hypotheses do not explain the eosinophilic proliferation in certain subjects.

Keywords: Eosinophilia, tumor necrosis factor-alpha inhibitors, etanercept, golimumab, hematologic side effects, therapy.